NEW YORK (GenomeWeb) — Transgenomic said today that it has signed a licensing deal with the Dana-Farber Cancer Institute for exclusive worldwide rights to develop and commercialize multiplexed versions of its ICE COLD-PCR technology.

The new license covers all fields and applications of the multiplexed technology, enabling the simultaneous detection of multiple DNA mutations from a single liquid sample such as blood or urine, Transgenomic said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.